ClinicalTrials.gg
CompletedNCT02035605Updated Dec 19, 2020

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

A Phase 1 interventional study of ALN-AT3SC and Sterile Normal Saline (0.9% NaCl) in Hemophilia A and Hemophilia B, sponsored by Sanofi. Completed at 14 sites in 5 countries. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Enrollment
7th of 10
51 · median 70
Started
2014
the only one that year
Phase 1
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
4 of 10
Sanofi

Among the 10 studies testing fitusiran in Hemophilia A, this one is the 7th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 1st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of ALN-AT3SC in healthy volunteers and Hemophilia A or B patients.

03

Conditions studied

  • Hemophilia A
  • Hemophilia B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A (SAD phase) inclusion:

  • Healthy adult males aged 18 to 40 years inclusive at Screening.
  • Subjects with adequate complete blood counts and liver function tests.
  • Willing to provide written and willing to comply with study requirements.

Part B \& C (MAD \& MD phase) inclusion:

  • Adult male hemophilia patients aged 18 to 65 years inclusive at Screening.
  • Patients with adequate complete blood counts and liver function tests.
  • Patients with moderate or severe, clinically stable hemophilia A or B (Factor VIII or Factor IX ≤5%).
  • Willing to provide written informed consent and willing to comply with study requirements

Part D (MD Phase in patients with inhibitors) Inclusion:

  • Same as Parts B/C
  • A Bethesda inhibitor assay > 0.6 BU/mL

Exclusion criteria

Exclusion Criteria:

Part A (SAD phase) exclusion:

  • Subjects with a personal history and/or family history of venous thromboembolism (VTE)
  • Subjects with a known co-existing thrombophilic disorder
  • Subjects with a history of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc.
  • Subjects with a history of serious mental illness that includes, but is not limited to schizophrenia, bipolar disorder, severe depression requiring hospitalization or pharmacological intervention.
  • Subjects who have a history or presence of cardiovascular, respiratory, gastrointestinal, renal, hematological, lymphatic, neurological, musculoskeletal, genitourinary, immunological including osteoarthritis and other inflammatory diseases, dermatological including rash, eczema, dermatitis, or connective tissue diseases or disorders.

Part B \& C (MAD \& MD phase) exclusion:

  • Patients with a current serious mental illness that, in the judgment of the Investigator, may compromise patient safety, ability to participate in all study assessments, or study integrity.
  • Patients who have a clinically relevant history or presence of cardiovascular, respiratory, gastrointestinal, renal, neurological, inflammatory or other diseases that in the judgment of the investigator precludes their participation in the study.
  • Patients with a known co-existing thrombophilic disorder
  • Patients with a history of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc.
  • Patients who are known to be positive and have a \<400 cells/μL

Part D (MD Phase in patients with inhibitors) exclusion:

  • Same as Parts B/C
  • Patients who are known to be HIV positive and have a CD4 count \<200 cells/μL
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    ALN-AT3SC

    Drug: ALN-AT3SC

  • Placebo comparator
    Sterile Normal Saline (0.9% NaCl)

    Drug: Sterile Normal Saline (0.9% NaCl)

Interventions

  • Ascending doses of ALN-AT3SC by subcutaneous (sc) injection

  • DrugSterile Normal Saline (0.9% NaCl)

    Calculated volume to match active comparator

06

What researchers measure

Primary outcomes

  1. The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation.

    Time frame: Part A (SAD phase): through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112

Secondary outcomes

  1. The pharmacokinetics (PK) of ALN-AT3SC as characterized by plasma PK profiles and urine samples.

    Time frame: Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112

  2. The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma AT levels.

    Time frame: Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112

  3. The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma TG.

    Time frame: Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112

07

Study locations

14 sites
  • Clinical Trial Site
    Pittsburgh, Pennsylvania, United States
  • Clinical Trial Site
    Plovdiv, Bulgaria
  • Clinical Trial Site
    Sofia, Bulgaria
  • Clinical Trial Site
    Varna, Bulgaria
  • Clinical Trial Site
    Kirov, Russian Federation
  • Clinical Trial Site
    Moscow, Russian Federation
  • Clinical Trial Site
    St. Petersburg, Russian Federation
  • Clinical Trial Site
    St. Gallen, Switzerland
  • Clinical Trial Site
    Zurich, Switzerland
  • Clinical Trial Site
    Glasgow, United Kingdom
  • Clinical Trial Site
    London, NW3 2QG, United Kingdom
  • Clinical Trial Site
    London, SE1 1YR, United Kingdom
  • Clinical Trial Site
    Manchester, United Kingdom
  • Clinical Trial Site
    Truro, United Kingdom
08

References and documents

Publications

  • Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I, Kazmi R, Chowdary P, Gercheva-Kyuchukova L, Mamonov V, Timofeeva M, Soh CH, Garg P, Vaishnaw A, Akinc A, Sorensen B, Ragni MV. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 Aug 31;377(9):819-828. doi: 10.1056/NEJMoa1616569. Epub 2017 Jul 10. PubMed 28691885 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jul 2017, 42 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 42 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2014
First posted
Jan 14, 2014
StartActual
Jan 20, 2014
Primary completionActual
Jul 20, 2017
CompletionActual
Jul 20, 2017
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02035605
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 14, 2014
Start date
Jan 20, 2014
Primary completion
Jul 20, 2017
Completion
Jul 20, 2017
Last update
Dec 19, 2020

Study contacts

Kate Madigan, MD
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion